Navigation Links
Oxitec Responds to University of Panama's 'Forum on Transgenic Mosquitoes'
Date:3/22/2012

LONDON, March 22, 2012 /PRNewswire/ -- The University of Panama held a 'Forum on Transgenic Mosquitoes' on Wednesday 21st March 2012. Unfortunately, all members of the panel at this event have previously registered on repeated occasions as entrenched opposition to the use of transgenic technologies, ensuring that a balanced and productive discussion could not take place. Oxitec, which in 2010 entered into a partnership with the Gorgas Institute in Panama to evaluate a new approach to combating the Dengue mosquito, Aedes aegypti, is disappointed not to have been granted the opportunity to participate fully on this occasion.

At Oxitec we recognise that openness, transparency and public discourse are central to the success of our approach. Oxitec is happy to engage in this process. We hope that in future all public debate will take into account the need for a balanced discussion.

Hadyn Parry, CEO of Oxitec, said:

"As with any new technology, our approach should be examined through expert review and the regulatory process. Experts need to be able to ask questions, and regulators need to determine the conditions for trials. Oxitec is no exception. We see our approach as potentially being an important part in the fight against Dengue.  We are fully committed to the evaluation process and engaging with the public, media and experts. "

To this end, we have taken a number of steps, including:

  • Organization and participation in technical symposia (2009/2010) involving a range of Panamanian and international stakeholders to debate the use of transgenic mosquitoes in Panama as part of a World Health Organisation (WHO) project on genetic control methods against mosquito vectors in disease endemic countries.
  • The organization of a technical symposium (which took place on October 26th , 2011) involving Panamanian academics, government officials, the Pan-American Health Organization and community leaders to debate the use of transgenic mosquitoes in Panama.
  • The organization of a community meeting in Nuevo Chorillo (an area of interest), which took place on November 8th, 2011. This event had an open invitation which allowed us to explain our approach and discuss issues and concerns with members of the public and contribute to media coverage at a local and national level.
  • Complete compliance with Panama's legislation, including the filling of permit applications and detailed briefings (both in writing and in person) presented to national regulatory bodies.

Oxitec is committed to a fully open and transparent relationship with all who wish to find out more about our solutions. Please send any questions to info@oxitec.com, or media enquiries to mediarelations@oxitec.com, tel : +44 (0) 1235 832 393

Notes to editors:

About Oxitec (www.oxitec.com)

Oxitec is a British company pioneering a new approach to combating dengue fever. The Oxitec solution harnesses advanced genetics to create 'sterile' male insects to combat insect-borne diseases. Dengue fever, which at conservative estimate infects at least 50 million people a year, is a growing problem in Panama and across the globe. Currently, mosquito populations are controlled by chemical pesticides which are indiscriminate and have not stopped the spread of the disease. The Oxitec approach has the potential to make a major contribution to global health by combating insects responsible for serious diseases such as dengue fever.


'/>"/>
SOURCE Oxitec
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Squamous Cell Cancer Responds to SPDT Therapy
2. Bunge Responds to Syngenta Suit
3. HCCS Responds to Recent Tornados, Earthquakes and Flooding With Free Online Training Course for Disaster Preparedness
4. Virtual reality helps researchers track how brain responds to surroundings
5. Burrill & Company Responds to Recent Press Coverage About Biopark Investment at Elk Run
6. China Biologic Products Responds to Allegations on Financial Websites
7. Datafarm Responds to Health Canada's Announcement of Hybrid eCTD Submission Procedural Simplification
8. China Sky One Medical, Inc. Responds to Concerns Regarding Filed Financial Reports
9. Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases
10. Immucor Responds To FDA Notice
11. Sanofi Pasteur Responds to Nations Need for Hib Vaccine With Increased Supply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... ... 11, 2017 , ... Singh Biotechnology today announced that the ... its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single ... the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation of ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder ... local San Diego Rotary Club. The event entitled “Stem Cells and ... had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
Breaking Biology News(10 mins):